ImmunoPrecise Antibodies (IPA) has released an update.
ImmunoPrecise Antibodies Ltd. has appointed Kristin Taylor as their permanent Chief Financial Officer, after her tenure as Interim CFO since September 2023. With a wealth of experience in financial leadership roles across various companies, Taylor’s expertise is expected to drive growth and strategic initiatives at the AI-driven biotherapeutic company. CEO Jennifer Bath expresses confidence in Taylor’s capabilities to lead the financial operations of ImmunoPrecise, which specializes in advanced antibody discovery and biologics development.
For further insights into IPA stock, check out TipRanks’ Stock Analysis page.
